Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 26,782 |
|
|||||
| News | - | ||||||
| Day High | 3.12 | Low High |
|||||
| Day Low | 2.98 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Trevi Therapeutics Inc | TRVI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.01 | 0.33% | 3.02 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.02 | 2.98 | 3.12 | 3.02 | 3.01 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 528 | 26,782 | $ 3.04 | $ 81,479 | - | 0.97 - 4.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:42:10 | 1 | $ 3.07 | USD |
Trevi Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 192.85M | 63.86M | - | 0 | -29.07M | -0.46 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Trevi Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRVI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.50 | 3.12 | 2.50 | 2.92 | 190,301 | 0.52 | 20.80% |
| 1 Month | 3.08 | 3.20 | 2.3501 | 2.85 | 191,054 | -0.06 | -1.95% |
| 3 Months | 1.56 | 4.00 | 1.5187 | 2.91 | 319,932 | 1.46 | 93.59% |
| 6 Months | 1.68 | 4.00 | 0.97 | 1.93 | 358,332 | 1.34 | 79.76% |
| 1 Year | 3.26 | 4.00 | 0.97 | 2.12 | 291,422 | -0.24 | -7.36% |
| 3 Years | 2.32 | 4.6834 | 0.46 | 2.16 | 414,644 | 0.70 | 30.17% |
| 5 Years | 9.50 | 10.62 | 0.46 | 2.37 | 272,193 | -6.48 | -68.21% |
Trevi Therapeutics Description
| Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease. |
